Table 5.
SARS-CoV2 infection, severe infection and death in patients treated with calcifediol and controls, according to CKD stages
| Patients on stages 1–3 CKD | Calcifediol (n = 130,323) | Controls (n = 263,873) | Univariate analysis3 | Multivariate analysis4 | ||
|---|---|---|---|---|---|---|
| HR (CI 95%) | p | HR (CI 95%) | p | |||
| SARS-CoV2 infection1, n (%) | 5351 (4.1) | 10,833 (4.1) | 1.00 (0.97–1.03) | 0.96 | – | NS |
| Severe COVID-192, n (%) | 893 (0.7) | 1813 (0.7) | 1.00 (0.92–1.08) | 0.94 | – | NS |
| COVID-19 mortality, n (%) | 796 (0.6) | 1614 (0.6) | 1.00 (0.92–1.09) | 0.97 | – | NS |
| Patients on stages 4–5 CKD | Calcifediol (n = 4380) | Controls (n = 5533) | HR (CI 95%) | p | HR (CI 95%) | p |
|---|---|---|---|---|---|---|
| SARS-CoV2 infection1, n (%) | 311 (7.1) | 568 (10.3) | 0.68 (0.59–0.78) | < 0.001 | 0.77 (0.67–0.88) | < 0.001 |
| Severe COVID-192, n (%) | 144 (3.3) | 260 (4.7) | 0.69 (0.57–0.85) | < 0.001 | 0.78 (0.63–0.96) | 0.018 |
| COVID-19 mortality, n (%) | 138 (3.2) | 245 (4.4) | 0.71 (0.57–0.87) | 0.001 | 0.83 (0.67–1.02) | 0.077 |
CKD chronic kidney disease
1Positive PCR or clinical diagnosis of SARS-CoV2 infection
2Composite outcome of need for non-invasive mechanical ventilation, orotracheal intubation, mechanical ventilation, intensive care unit admission or death
3Unadjusted Cox regression analysis
4Cox regression analysis controlling for all covariates